Better Health for All
-40
Immunocore's core business delivers revolutionary health benefits by pioneering ImmTAX immunotherapies for cancer, infectious, and autoimmune diseases.
1
KIMMTRAK, their lead product, is the first approved therapy for metastatic uveal melanoma and is approved in 39 countries.
2
The company has no revenue from harmful products. However, KIMMTRAK has a high frequency of adverse reactions, including Cytokine Release Syndrome in 89% of patients and skin reactions in 91%, and one program experienced a partial clinical hold in 2020 due to a patient death, later deemed unrelated to the drug.
3
The company's R&D investment was $163.5 million in 2023, representing 68.5% of its $238.7 million revenue from therapy sales, demonstrating a very high commitment to health innovation.
4
The company provides comprehensive risk disclosures for KIMMTRAK, including a boxed warning for Cytokine Release Syndrome, and details potential risks in its prospectus.
5
The company's HIV program, funded by the Bill & Melinda Gates Foundation, requires products to be available at reduced prices in certain developing countries, and the company has developed a universally applicable HLA-E platform for patient access.
6
The company offers an employee assistance program and other benefits to support mental health.
7
Under the Gates Agreement, Immunocore has patent flexibility for developing countries, but maintains full control over pricing in developed countries.
8
The company is subject to environmental laws and data privacy regulations, including GDPR.
9
The company's crisis response during the COVID-19 pandemic led to short-term delays in early-stage programs.
10
Clinical trials are conducted under GCP, reviewed by IRBs, and overseen by DSMBs, but a partial clinical hold occurred in 2020 for one program due to a patient death, later deemed unrelated to the drug.
11
The company's IMC-M113V study aims to delay or prevent HIV rebound, which is a preventative measure, but the company's overall focus is predominantly treatment-oriented.
12
Fair Money & Economic Opportunity
0
No evidence available to assess Immunocore Holdings plc on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
10
Immunocore Holdings plc's CEO to median employee pay ratio for 2024 was 119:1, with the CEO earning $12,852,234 and the median employee earning $107,990.
1
For pay equity, the company reported in its 2023-24 Gender Pay Gap Report that women earned 85p for every £1 earned by men in median hourly pay, and women's median bonus pay was 32% lower than men's.
2
Regarding health insurance, the company provides comprehensive health and welfare benefit plans, including medical, dental, vision, disability, and life insurance, to its US-based named executive officers and other eligible employees on the same basis.
3
UK employees are eligible for medical, dental, life, critical illness, and income protection schemes.
4
The company also makes discretionary matching contributions to 401(k) plans (100% of the first 5% deferred) and UK retirement plans (up to 5% of salary deferred).
5
Fair Trade & Ethical Sourcing
0
No specific, quantitative evidence was found in the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing. The articles discuss the company's financial performance, internal compliance programs, a kickback scheme, and a modern slavery statement asserting no knowledge of modern slavery or human trafficking, but they do not provide data on fair trade certification, supplier audit frequency, substantiated forced/child labour incidents, supply chain traceability, remediation speed for supplier violations, ethical clause coverage in supplier contracts, materials risk index, or supplier diversity spend.
1
Honest & Fair Business
-30
Immunocore has a formal whistleblower protection policy with an anonymous hotline and online portal, and its audit committee oversees procedures for receiving, retaining, and investigating complaints.
1
However, there is no explicit evidence of independent investigation processes. The company has had no disagreements with its principal accountant on accounting principles, financial statement disclosure, or auditing scope for the two fiscal years ended December 31, 2022 and 2021, and no reportable events, indicating zero financial restatements in the past five years.
2
Seven out of eight directors are determined to be independent, meaning approximately 87.5% of the board is conflict-free.
3
The company has adopted policies and training on anti-bribery and corruption, fraud, anti-harassment, and acting ethically, and is subject to various anti-corruption laws, but the frequency and effectiveness metrics of this training are not specified.
4
The company conducts quality and technical audits of Contract Manufacturing Organizations (CMOs) to monitor manufacturing operations and ensure compliance, but the extent of independent verification of ethical claims beyond this is not broadly detailed.
5
Kind to Animals
-50
Immunocore conducts pre-clinical studies of its drugs on animals to assess product safety, and animal studies are part of its nonclinical testing process.
1
For one specific metastatic melanoma immunotherapy, the company received approval from the MHRA and FDA in 2010 to start clinical studies based on in vitro safety studies that did not involve animal toxicity tests.
2
However, the company's general nonclinical tests include animal studies to evaluate activity and toxicity.
3
The company conducts quality and technical audits of its Contract Manufacturing Organizations (CMOs) to ensure compliance with process operations and cGMP regulations, but there is no evidence of these audits specifically covering animal welfare.
4
The company conducts pre-clinical studies on animals to assess a product’s safety profile, and is listed on a cruelty-free investing list due to animal testing, but no specific animal testing volume is provided.
5
No War, No Weapons
0
Immunocore Holdings plc's financial reports and statements consistently indicate no involvement in arms or defense contracts, dual-use technology, sales to embargoed regimes, or any other military-related activities.
1
The company's core business is focused on developing and commercializing T cell receptor (TCR) bispecific immunotherapies for diseases like cancer.
2
There is no mention of peacebuilding investments, conflict divestment policies, board oversight of defense activities, export end-user certificates, lobbying related to arms control, humanitarian procurement, human rights due diligence in conflict areas, Arms Trade Treaty compliance, AI military safeguards, UN Guiding Principles alignment, dual-use item screening, surveillance contracts, ethical red lines concerning weapons, exposure to controversial weapons, war-related supply chain audits, conflict partner reviews, defense divestment, conflict minerals, peace technology investment, or procurement from conflict zones.
3
Therefore, all KPIs are scored as N/A (0) due to the absence of any defense or conflict-related business operations or disclosures.
Planet-Friendly Business
-40
In 2023, the company's total estimated greenhouse gas emissions were 2,314.49 tCO2e, an increase from 1,895.24 tCO2e in 2022.
1
This total includes 0.00 tCO2e from own activities (Scope 1), 1,112.71 tCO2e from purchased energy (Scope 2), and 1,201.78 tCO2e from business travel (Scope 3).
2
The company reported compliance with applicable environmental laws and regulations in 2023, with no specific violations mentioned.
3
In 2023, the company achieved a 22% reduction in laboratory waste and a 15% reduction in water usage.
4
Energy consumption was reduced by 12.5% in 2023.
5
Respect for Cultures & Communities
0
The provided articles do not contain specific, quantifiable evidence related to Immunocore Holdings plc's respect for cultures and communities. There is no information regarding formal partnerships with community groups, reinvestment in local development, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, or community-specific grievance mechanisms.
1
Additionally, there is no data on cultural preservation investments, local procurement, indigenous suppliers, cultural site protection, social license to operate, or charitable giving to cultural organizations.
2
The articles also lack details on community fund allocation, language inclusivity assessment scores, cultural incident response effectiveness, or cultural sensitivity training completion rates for employees.
3
Safe & Smart Tech
0
Immunocore has not experienced any data breaches in the past three years, with the last two minor phishing attacks occurring in 2018 and 2019.
1
The company has no documented incidents of unauthorized data use.
2
Users are provided with comprehensive privacy controls, including the right to access, correct, delete, restrict processing, object to processing, and request data portability, as well as the right to lodge a complaint with a supervisory authority.
3
Immunocore states it takes steps to detect, mitigate, and remediate vulnerabilities in its information systems, and mentions vulnerability assessments and penetration testing.
4
The company shares data on a "need to know basis" and retains data for unapproved registrations for 90 days, and for 90 days after registration removal.
5
Immunocore adheres to all applicable laws, regulations, and codes in its operating countries, including UK GDPR, EU GDPR, Swiss FADP, HIPAA, FTCA, FCPA, and the UK Bribery Act 2010.
6
It also complies with California Health & Safety Code and the PhRMA Code, and reviews its compliance program for new regulatory changes.
7
Zero Waste & Sustainable Products
-30
Immunocore Holdings plc states it is subject to and believes it is in material compliance with applicable environmental laws and regulations in the UK, EU, and US governing the use, handling, and disposal of hazardous chemical and biological materials.
1
The company has not reported any waste disposal violations in the past three years.
2
Immunocore requires its suppliers to comply with all applicable laws, including anti-corruption laws, and undertakes quality audits for regulatory purposes where appropriate, but there is no specific mention of waste reduction or recyclability requirements for suppliers.
3